Starting July 1, 2026, millions of Medicare beneficiaries will be able to fill prescriptions for GLP-1 weight-loss drugs at a flat $50 per month, a price point far below the retail cost of medications like Wegovy and Zepbound. The 18-month demonstration, called the Medicare GLP-1 Bridge, runs through Dec. 31, 2027, and sits entirely outside the standard Part D drug benefit. That structural choice means the federal government, not private insurers, absorbs the difference between what patients pay and what drugmakers charge, creating open-ended taxpayer exposure that scales directly with enrollment and has no published spending cap. According to a CMS announcement, the program is intended as a time-limited pathway while longer-term coverage policies for anti-obesity medications are evaluated.
Why the $50 copay sits outside normal Part D cost controls
The Bridge demonstration was designed to bypass the usual Part D coverage and payment flow. Plans that administer Part D do not bear financial risk for GLP-1 prescriptions filled under the program, according to CMS program documents. The $50 monthly copay does not count toward a beneficiary’s true out-of-pocket spending, known as TrOOP, and does not apply to the Part D deductible. In a standard Part D benefit, those accumulation rules give insurers a financial stake in managing how many prescriptions get filled and at what price. When spending crosses certain thresholds, both plans and the government share costs through risk corridors and reinsurance formulas that create mutual incentives to control utilization.
Removing GLP-1 spending from that framework eliminates the built-in friction. Plans have no reason to impose prior authorization hurdles, step therapy, or formulary restrictions on Bridge-eligible drugs because the cost never touches their balance sheets. CMS guidance to Part D sponsors underscores that these claims are carved out of normal benefit administration, with the agency paying pharmacies directly based on a fixed net price arrangement with manufacturers.
The practical result is that demand will be shaped almost entirely by patient interest and prescriber willingness, with no insurer gatekeeping to slow uptake. For a drug class already generating enormous consumer demand in the commercial market, that dynamic could produce enrollment rates well above what a traditional Part D expansion would generate. Physicians who previously hesitated to prescribe GLP-1s to Medicare patients because of cost barriers may now view the $50 copay as a compelling justification, especially for beneficiaries with obesity-related comorbidities.
Federal cost exposure at $245 per monthly supply
CMS has published the manufacturer net price for drugs dispensed through the Bridge: $245 per monthly supply. With beneficiaries paying $50, the federal government covers at least $195 per prescription per month before any administrative or dispensing costs. Three branded products are eligible: Foundayo, Wegovy injection and tablets, and Zepbound KwikPen. Foundayo, an oral pill containing the active ingredient orforglipron, was recently cleared by the FDA as the first new molecular entity approved under the National Priority Voucher Program.
The addition of an oral option could accelerate enrollment beyond what injectable-only coverage would attract. Many Medicare beneficiaries who resisted self-injection may now find a daily pill more accessible. CMS has not published enrollment projections, utilization caps, or aggregate cost modeling for the Bridge. Without those guardrails, the total federal outlay depends on a single variable: how many people sign up. If even a modest share of the Medicare population with obesity or overweight fills a monthly prescription, the cumulative cost over 18 months could reach billions of dollars, a figure that grows larger with every additional enrollee and every month of sustained use.
Clinical eligibility and program design choices
Under the Bridge, beneficiaries must meet clinical criteria tied to obesity or overweight with related conditions, and prescriptions must be written for chronic weight management rather than diabetes alone. CMS positions these guardrails as a way to focus spending on patients most likely to see health benefits from sustained weight loss. However, because the program does not run through conventional Part D utilization management tools, the rigor of those criteria will largely depend on prescriber documentation and pharmacy-level verification.
The demonstration’s time-limited nature is another key design choice. By ending on Dec. 31, 2027, CMS retains flexibility to adjust or discontinue coverage based on emerging evidence about both clinical outcomes and budget impact. Yet the sunset date also creates a potential coverage cliff. Beneficiaries who start therapy under the Bridge may face sharply higher out-of-pocket costs or loss of access if Congress or CMS does not establish a permanent coverage pathway before the demonstration expires. That uncertainty could influence both patient decisions to initiate treatment and clinicians’ willingness to prescribe.
Balancing access, evidence, and fiscal risk
The Medicare GLP-1 Bridge reflects a policy gamble: that broad, low-cost access to powerful weight-loss medications will yield enough health gains to justify substantial federal spending, even in the absence of traditional Part D cost controls. Supporters argue that rapid uptake could reduce downstream costs from heart disease, diabetes, and other obesity-related conditions. Skeptics counter that without clear enrollment limits, robust real-world evidence requirements, or shared financial risk for plans and manufacturers, the program exposes taxpayers to escalating bills with no guaranteed offsetting savings.
How many beneficiaries enroll, how long they stay on therapy, and what clinical outcomes they experience will determine whether the Bridge is remembered as a prudent investment in population health or an expensive experiment in bypassing Medicare’s usual guardrails. For now, the only certainty is that starting in July 2026, cost will no longer be the primary barrier keeping many older Americans from trying GLP-1 weight-loss drugs-and that the federal government will pick up most of the tab.
